Efrat Eliyahu

Title: Efrat Eliyahu: Innovator in Sphingolipid-Metabolizing Proteins

Introduction

Efrat Eliyahu is a notable inventor based in New York, NY (US). He has made significant contributions to the field of biomedical research, particularly in the area of sphingolipid metabolism. With a total of two patents to his name, Eliyahu's work focuses on mitigating tissue damage caused by various diseases.

Latest Patents

Eliayhu's latest patents include "Anc80 encoding sphingolipid-metabolizing proteins for mitigating disease-induced tissue damage." This patent discusses the use of sphingolipid-metabolizing proteins to minimize tissue damage resulting from conditions such as pulmonary arterial hypertension (PAH). The delivery of these proteins is facilitated through expression from an Anc80 vector. Another significant patent is "Acid ceramidase and mammalian cell survival," which relates to methods for promoting cell survival by treating cells with acid ceramidase. This patent also includes a kit for enhancing ex vivo cell survival and a method for predicting in vitro fertilization outcomes in female subjects.

Career Highlights

Eliayhu has worked with prestigious institutions, including Mount Sinai School of Medicine and the Icahn School of Medicine at Mount Sinai. His research has contributed to advancements in understanding and treating diseases related to sphingolipid metabolism.

Collaborations

Eliayhu has collaborated with notable colleagues such as Edward Howard Schuchman and Nataly Shtraizent, who have also made significant contributions to the field.

Conclusion

Efrat Eliyahu's innovative work in sphingolipid metabolism and cell survival has the potential to impact medical treatments significantly. His patents reflect a commitment to advancing biomedical research and improving patient outcomes.